We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

13 hedge funds and large institutions have $1.37M invested in Cellectar Biosciences in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

223% more capital invested

Capital invested by funds: $426K → $1.37M (+$948K)

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

8% more funds holding

Funds holding: 12 → 13 (+1)

0.06% more ownership

Funds ownership: 0% → 0.06% (+0.06%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
13
Holders Change
+1
Holders Change %
+8.33%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WC
Wexford Capital
Florida
+$1.33M
2
AIC
AWM Investment Company
New York
+$376K
3
SFM
Sphera Funds Management
Israel
+$344K
4
Renaissance Technologies
Renaissance Technologies
New York
+$230K
5
Morgan Stanley
Morgan Stanley
New York
+$86K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$59K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$44K
3
Citadel Advisors
Citadel Advisors
Florida
-$35K
4
State Street
State Street
Massachusetts
-$34K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$30.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
WC
1
Wexford Capital
Florida
$750K +$1.33M +1,125 New
SFM
2
Sphera Funds Management
Israel
$263K +$344K +292 New
Renaissance Technologies
3
Renaissance Technologies
New York
$176K +$230K +195 New
Morgan Stanley
4
Morgan Stanley
New York
$67K +$86K +73 +3,650%
Vanguard Group
5
Vanguard Group
Pennsylvania
$50K -$30.6K -26 -32%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$31K +$40K +34 New
US Bancorp
7
US Bancorp
Minnesota
$9K – – –
AIC
8
AWM Investment Company
New York
$9K +$376K +319 +886%
UBS Group
9
UBS Group
Switzerland
$8K +$9.42K +8 New
VCM
10
Vigilant Capital Management
Maine
$6K +$8.24K +7 New
IGGA
11
Iron Gate Global Advisors
Utah
$2K -$8.24K -7 -70%
SIM
12
Sonora Investment Management
Arizona
$2K – – –
Bank of America
13
Bank of America
North Carolina
$1K +$1.18K +1 New
VF
14
Virtu Financial
New York
– -$59K -32 Closed
Geode Capital Management
15
Geode Capital Management
Massachusetts
– -$44K -24 Closed
Citadel Advisors
16
Citadel Advisors
Florida
– -$35K -19 Closed
State Street
17
State Street
Massachusetts
– -$34K -18 Closed
TSS
18
Two Sigma Securities
New York
– -$20K -11 Closed
Northern Trust
19
Northern Trust
Illinois
– -$18K -10 Closed
APA
20
American Portfolios Advisors
New York
– -$1 – –

CLRB Hedge Fund Activity: Q3 2018 in Review

13 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2018, worth a combined $1.37M — up 223% from $426K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CLRB positions and 6 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Wexford Capital, opening a new position worth an estimated $1.33M. The largest seller was Virtu Financial, exiting entirely with an estimated $59K sold.

  • 13 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2018, up from 12 in Q2 2018.
  • Funds reported $1.37M of Cellectar Biosciences stock for Q3 2018, up 223% quarter-over-quarter.
  • 7 funds opened new Cellectar Biosciences positions in Q3 2018 and 6 closed out, a net change of +1 holder.
  • The largest Cellectar Biosciences buyer in Q3 2018 was Wexford Capital, an estimated $1.33M added.
  • The largest Cellectar Biosciences seller in Q3 2018 was Virtu Financial, an estimated $59K sold.

Based on aggregated 13F filings for Q3 2018.